Integra LifeSciences Holdings Corporation (NASDAQ:IART) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday. The brokerage currently has a $55.00 price objective on the life sciences company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 11.45% from the stock’s previous close.

According to Zacks, “Over the last six months, Integra Lifesciences has been trading above the broader industry. Moreover, the strong year over year increase in revenue on the back of solid performance of its Orthopedics and Tissue Technologies’ segment buoys optimism. We believe the company’s recent product diversification bolstered investors’ confidence, thereby boosting the stock price further. On the flip side, the company exited the second quarter of 2017 on somewhat disappointing note with earnings in line with the estimates and revenues missing the mark. We are concerned about the currency headwind that is expected to affect Integra’s financial performance in the rest of 2017. Also, contraction in adjusted operating margin and adjusted gross margin adds to the woes.”

Several other equities analysts have also recently weighed in on IART. Oppenheimer Holdings, Inc. set a $60.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Saturday, June 24th. Cantor Fitzgerald set a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Jefferies Group LLC reiterated a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research report on Sunday, September 10th. Barclays PLC reiterated an “equal weight” rating and set a $53.00 price objective (up from $47.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Tuesday, September 12th. Finally, BidaskClub cut shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Integra LifeSciences Holdings Corporation currently has a consensus rating of “Buy” and an average price target of $54.27.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) traded down 0.16% during midday trading on Tuesday, reaching $49.35. The company’s stock had a trading volume of 407,325 shares. The stock has a market capitalization of $3.85 billion, a PE ratio of 60.18 and a beta of 0.72. Integra LifeSciences Holdings Corporation has a 12 month low of $37.71 and a 12 month high of $56.42. The stock’s 50 day moving average is $50.68 and its 200 day moving average is $49.30.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.45. The firm had revenue of $282.16 million for the quarter, compared to analyst estimates of $283.58 million. Integra LifeSciences Holdings Corporation had a net margin of 6.27% and a return on equity of 16.79%. The firm’s quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.40 earnings per share. On average, analysts forecast that Integra LifeSciences Holdings Corporation will post $1.91 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Integra LifeSciences Holdings Corporation (IART) Upgraded to Buy by Zacks Investment Research” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/10/10/integra-lifesciences-holdings-corporation-iart-upgraded-to-buy-by-zacks-investment-research.html.

In related news, Director Donald E. Morel, Jr. purchased 10,000 shares of the stock in a transaction dated Friday, August 4th. The shares were acquired at an average cost of $49.25 per share, for a total transaction of $492,500.00. Following the acquisition, the director now directly owns 29,612 shares in the company, valued at approximately $1,458,391. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara B. Hill purchased 5,050 shares of the stock in a transaction dated Tuesday, August 1st. The shares were bought at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the acquisition, the director now owns 44,772 shares in the company, valued at $2,208,602.76. The disclosure for this purchase can be found here. Over the last 90 days, insiders have bought 17,550 shares of company stock worth $864,842. 21.50% of the stock is currently owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in IART. BlackRock Inc. lifted its stake in shares of Integra LifeSciences Holdings Corporation by 307,726.8% in the 1st quarter. BlackRock Inc. now owns 7,455,564 shares of the life sciences company’s stock valued at $314,104,000 after purchasing an additional 7,453,142 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Integra LifeSciences Holdings Corporation by 116.7% in the 1st quarter. Vanguard Group Inc. now owns 5,656,048 shares of the life sciences company’s stock valued at $238,289,000 after purchasing an additional 3,046,488 shares during the last quarter. Capital Research Global Investors lifted its stake in shares of Integra LifeSciences Holdings Corporation by 227.0% in the 2nd quarter. Capital Research Global Investors now owns 3,897,288 shares of the life sciences company’s stock valued at $212,441,000 after purchasing an additional 2,705,488 shares during the last quarter. Champlain Investment Partners LLC lifted its stake in shares of Integra LifeSciences Holdings Corporation by 125.2% in the 1st quarter. Champlain Investment Partners LLC now owns 4,438,760 shares of the life sciences company’s stock valued at $187,005,000 after purchasing an additional 2,468,145 shares during the last quarter. Finally, Janus Henderson Group PLC acquired a new stake in shares of Integra LifeSciences Holdings Corporation in the 2nd quarter valued at $112,068,000. 84.90% of the stock is owned by institutional investors and hedge funds.

Integra LifeSciences Holdings Corporation Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Get a free copy of the Zacks research report on Integra LifeSciences Holdings Corporation (IART)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with MarketBeat.com's FREE daily email newsletter.